Trial reportPsychopharmacology2013
Nicotine differentially modulates antisaccade eye-gaze away from emotional stimuli in nonsmokers stratified by pre-task baseline performance.
Trial report in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Increased dopamine availability magnifies nicotine effects on cognitive control: A pilot study.Journal of psychopharmacology (Oxford, England) · 2020Trial
- Moderation of nicotine effects on covert orienting of attention tasks by poor placebo performance and cue validity.Pharmacology, biochemistry, and behavior · 2016Trial
- Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder.Journal of psychopharmacology (Oxford, England) · 2025Article
- Anhedonia in Nicotine Dependence.Current topics in behavioral neurosciences · 2022Review
- APOE genotype influences P3b amplitude and response to smoking abstinence in young adults.Psychopharmacology · 2021Article
- Cognitive performance effects of nicotine and industry affiliation: a systematic review.Substance abuse : research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
RATIONALE AND
objectiveStudies indicate that nicotine enhances some aspects of attention and executive functioning and attenuates the attentional salience of emotionally negative distractors. The purpose of this study was to assess whether nicotine can enhance executive control over prepotent responses in emotional contexts in nonsmokers and whether such enhancement is greater in individuals with low baseline performance (BP).
methodsThe antisaccade task (AST) measures the inhibition of the tendency to glance in the direction of the onset of a visual stimulus and thus is an index of control over prepotent responses. Ten male and 14 female nonsmokers wore nicotine and placebo patches on counterbalanced days that included emotional picture primes and targets.
resultsThere were significant beneficial effects of nicotine on antisaccade reaction time (RT). These beneficial effects occurred in individuals with poor and average BP, but not in high baseline performers. In slow baseline RT individuals, nicotine reduced RTs associated with negative targets in the left visual field (VF) and reduced RTs associated with positive and neutral targets in the right VF. In contrast, in the average baseline group, nicotine reduced RTs for positive targets in both VFs and neutral targets in the left VF.
conclusionsThe results suggest that nicotine may produce its effects by enhancing executive functions and that the differential effects as a function of VF, target emotion, and group may also reflect lateralized differences in the effects of nicotine on brain reactivity to emotional stimuli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.